Suzanne Sommer

Suzanne Sommer leads DDR drug discovery at the ICR with a focus on ATM kinase inhibitor development. Her program identified AZD0156 and AZD1390 as potent and selective ATM inhibitors, characterizing their activity as single agents and in combination with PARP inhibitors, radiotherapy, and temozolomide in ATM-deficient cancers. Her work has elucidated the synthetic lethal relationship between ATM loss and PARP inhibition. The DDR inhibitor candidates developed through her program have entered clinical trials as monotherapy and in combination with ATR and PARP inhibitors.